Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma

NCT00165633 is registered in ClinicalTrials.gov with Eisai Limited as lead sponsor.

NCT NCT00165633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00165633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
Lead sponsor
Eisai Limited
Phase
Phase 2/3
Overall status
Terminated
Start date
March 31, 2004
Completion date
March 31, 2007
Enrollment
540 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma